Sanofi/
Buying an autoimmune disease drug for $1.3 billion
Sanofi announced Thursday that it has agreed to buy the biopharmaceutical company’s autoimmune disease drug Dren Bio for $1.3 billion.
The experimental drug DR-0201, Dren Bio’s first antibody, targets certain immune cells to help eliminate B cells from the body.
The drug is being tested in two early-stage studies and has shown effective results in reducing B cells in laboratory and clinical studies.
Normally, B cells produce antibodies to fight infections, but in autoimmune diseases they also attack healthy tissue.
